Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | USP2 | O75604 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.41 |
| ▸ | GCGR | P47871 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 2/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5789108 | 0.89 | MAPK14 (0.57) | ADORA1MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL27224360 | 0.86 | MAPK14 (0.42) | ADORA1MAPK14CYP1A2USP2TSHR | |
| SCHEMBL27224359 | 0.84 | ALDH1A1 (0.60) | ADORA1MAPK14CYP1A2USP2TSHR | |
| SCHEMBL27224357 | 0.84 | MAPK14 (0.45) | ADORA1MAPK14CYP1A2USP2TSHR | |
| SCHEMBL4826188 | 0.83 | MAPK9 (0.56) | ADORA1MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL5787744 | 0.80 | CSNK1D (0.55) | MAPK14USP2MAPK11MAPK13MAPK12 | |
| SCHEMBL5847952 | 0.79 | MAPK9 (0.43) | MAPK14ALDH1A1MAPK11MAPK13MAPK12 | |
| SCHEMBL27413911 | 0.78 | KDM1A (0.52) | MAPK14CYP1A2USP2ALDH1A1MAPK11 | |
| SCHEMBL5741934 | 0.78 | AURKA (0.42) | ADORA1MAPK14ALDH1A1SRCKDR | |
| SCHEMBL6693653 | 0.78 | MAPK14 (0.45) | ADORA1MAPK14ALDH1A1MAPK11MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062401-A1 | METHODS OF TREATING NEUROLOGICAL DISORDERS | NEUMORA THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4626878-A1 | METHODS OF TREATING NEUROLOGICAL DISORDERS | Neumora Therapeutics, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| US-12371414-B2 | Methods of treating neurological disorders | Neumora Therapeutics, Inc. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20240294492-A1 | METHODS OF TREATING NEUROLOGICAL DISORDERS | Neumora Therapeutics, Inc. | 2024-09-05 | — | — | US | disclosed |
| US-20240246928-A1 | METHODS OF TREATING NEUROLOGICAL DISORDERS | Neumora Therapeutics, Inc. | 2024-07-25 | — | — | US | disclosed |
| WO-2024119067-A1 | METHODS OF TREATING NEUROLOGICAL DISORDERS | Neumora Therapeutics, Inc. (US) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024119067-A1 | METHODS OF TREATING NEUROLOGICAL DISORDERS | Neumora Therapeutics, Inc. (US) | 2024-06-06 | — | — | WO | disclosed |
| US-11993580-B1 | Methods of treating neurological disorders | Neumora Therapeutics, Inc. (US) | 2024-05-28 | — | — | US | disclosed |
| US-7026326-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2006-04-11 | — | — | US | disclosed |
| US-20050038010-A1 | Substituted heterocyclic compounds and methods of use | AMGEN, INC. | 2005-02-17 | — | — | US | disclosed |
| EP-1506186-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003099808-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11993580-B1 | Methods of treating neurological disorders | SMN1; SMN2, CLN6, PMP22 | ADORA1 1514/4885MAPK14 4388/4885CYP1A2 750/4885 |
| US-20240246928-A1 | METHODS OF TREATING NEUROLOGICAL DISORDERS | SMN1; SMN2, CLN6, PMP22 | ADORA1 1514/4885MAPK14 4388/4885CYP1A2 750/4885 |
| US-20260062401-A1 | METHODS OF TREATING NEUROLOGICAL DISORDERS | HCN2, HCN3, HCN1 | ADORA1 250/4885MAPK14 3748/4885CYP1A2 612/4885 |
| US-20240294492-A1 | METHODS OF TREATING NEUROLOGICAL DISORDERS | SMN1; SMN2, CLN6, PMP22 | ADORA1 1503/4885MAPK14 4360/4885CYP1A2 729/4885 |
| US-20050038010-A1 | Substituted heterocyclic compounds and methods of use | MYLK2, MYLK, MCL1 | ADORA1 813/4885MAPK14 2458/4885CYP1A2 1292/4885 |
| US-12371414-B2 | Methods of treating neurological disorders | SMN1; SMN2, CLN6, PMP22 | ADORA1 1514/4885MAPK14 4388/4885CYP1A2 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.